Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Seal, Stopping Eczema and Allergy Study
NCT03742414 · View on ClinicalTrials.gov ↗
Study Summary
This is a randomized, controlled trial designed for children who are have already developed atopic dermatitis (AD or eczema) by 12 weeks of age. The aim is to compare the effect of proactive sequential skin care, including the twice-daily use of a tri-lipid skin barrier cream (Epiceram) and proactive use of fluticasone propionate cream, against reactive AD therapy, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).
Conditions Studied
Interventions
- OTHER Standard of Care
- COMBINATION_PRODUCT Tri-lipid skin barrier cream (Epiceram)
- COMBINATION_PRODUCT Fluticasone propionate Cream 0.05%
Study Locations (5)
California
- Sean N. Parker Center for Allergy & Asthma Research at Stanford University — Palo Alto
Colorado
- Division of Pediatric Allergy and Clinical Immunology, National Jewish Health — Denver
Illinois
- University of Chicago — Chicago
Ohio
- Cincinnati Children's Hospital Medical Center — Cincinnati
London
- • King's College London and Guy's and St. Thomas' NHS Foundation Trust, UK — London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 398 participants |
| Start Date | 2021-06-30 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03742414
The ClinicalTrials.gov registry entry for NCT03742414 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 398 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kari Nadeau, MD, PhD, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 4 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 3 interventions — of which Standard of Care is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03742414 reports 5 study locations spanning 5 distinct geographic areas — top geographies include California, Colorado, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03742414 about?
NCT03742414 is a clinical study titled "Seal, Stopping Eczema and Allergy Study". This is a randomized, controlled trial designed for children who are have already developed atopic dermatitis (AD or eczema) by 12 weeks of age. The aim is to compare the effect of proactive sequential skin care, including the twice-daily use of a tri-lipid skin barrier cream (Epiceram) and proactiv...
What is the current status of trial NCT03742414?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 398 participants. The study started on 2021-06-30. Estimated completion is 2028-06-30.
What conditions does trial NCT03742414 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Eczema, Atopic Dermatitis Eczema, Eczema, Infantile. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03742414?
The interventions under investigation include: Standard of Care (OTHER), Tri-lipid skin barrier cream (Epiceram) (COMBINATION_PRODUCT), Fluticasone propionate Cream 0.05% (COMBINATION_PRODUCT). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03742414?
This trial is sponsored by Kari Nadeau, MD, PhD, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03742414 being conducted?
This trial has 5 study locations across California, Colorado, Illinois, Ohio, London. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.